BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In a phase I clinical trial (NCT01702064), the combination therapy of nilotinib and ruxolitinib resulted in undetectable BCR::ABL1 in 40% of CML patients after 6 months, as measured by RT-qPCR [101].